- Bayer's revenue is up in all of its divisions; net income is up 12.7%.
- I forecasted ongoing growth, especially in Pharma and CropSciences. I have been correct so far.
- I remain with my original conclusion: Bayer is an attractive investment.
- Bayer AG offers great fundamentals.
- Bayer AG yields 2% right now, dividend has been increased constantly over the past.
- Multiples are higher than those of peers, might not be the best time to buy right now.
There are no Transcripts on BAYZF.
Dec. 17, 2014, 4:57 PM
- A top Chinese government official says the country has approved Syngenta’s (NYSE:SYT) genetically modified Agrisure Viptera corn, one year after China began rejecting shipments of grain it said contained traces of the unapproved trait, according to U.S. Agriculture Secretary Tom Vilsack.
- Chinese Vice Premier Wang Yang said imports of the MIR 162 corn had been approved by China's Ministry of Agriculture, Vilsack says, adding that the ministry also approved imports of biotech soybeans developed by DuPont Pioneer (NYSE:DD) and Bayer CropScience (OTCPK:BAYZF, OTCPK:BAYRY).
- The import approvals do not represent a loosening of China's long regulatory review process for GMO crops, Vilsack says.
Dec. 15, 2014, 10:03 AM
- Germany's healthcare cost watchdog, the German Institute for Quality and Efficiency in Health Care, determines that Bayer's (OTCPK:BAYRY +0.9%) (OTCPK:BAYZF) eye drug Eylea (aflibercept) offers no additional benefit over Novartis' (NVS -0.6%) Lucentis (ranibizumab) for the treatment of diabetic macular edema. The agency's decision could affect the amount of reimbursement for Eylea.
- In January, the Institute came to the same conclusion for the indication of macular edema. Last year, it determined that it could not assess the potential advantages of Eylea in wet age-related macular degeneration because Bayer has not provided the relevant data.
- Eylea was developed by Regeneron Pharmaceuticals (REGN -1.5%) and licensed to Bayer in ex-U.S. territories.
Nov. 25, 2014, 11:11 AM
- China’s barriers to imports of some U.S. genetically modified crops are disrupting seed companies' plans for new product launches and keeping at least one variety out of the U.S. market altogether, Reuters reports.
- Dow AgroSciences (NYSE:DOW) and Syngenta (NYSE:SYT) are tightly controlling U.S. launches of new GMO seeds, telling farmers where they can plant new corn and soybean varieties and how can the use them, while Bayer CropScience (OTCPK:BAYZF, OTCPK:BAYRY) is keeping a new soybean variety on hold until it receives Chinese import approval.
- China is taking longer than in the past to approve new GMO crops and began rejecting U.S. imports a year ago, saying they were tainted with a GMO corn variety approved in the U.S. but not in China.
- Controlled launches are at best a temporary fix because they are costly, complicated and risk accidental contamination of other export grains, says the head of the U.S. Soybean Export Council.
Nov. 24, 2014, 4:04 PM
- Sources close to the matter say Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) is exploring the sale of its diabetes device business as it focuses on higher growth areas. The company is supposedly working with Credit Suisse on the potential deal. Observers believe the unit could fetch between €1B - 2B ($2.5B).
- Bayer also intends to jettison its plastics business.
Oct. 29, 2014, 2:48 PM
- Bayer (OTCPK:BAYZF, OTCPK:BAYRY) says its crop science unit agrees to acquire certain crop protection and land-management assets from DuPont (DD -1.7%) for an unspecified amount.
- The deal will enable Bayer to offer a broad range of products for weed control for farming, and will provide access to the growing forestry and range and pasture business segments in North America.
- DuPont will continue to sell its land management products outside of the five countries where the assets are located: the U.S., Canada, Mexico, Australia and New Zealand.
Oct. 22, 2014, 2:43 PM
- P-E firms are coveting Bayer's (OTCPK:BAYZF, OTCPK:BAYRY) €10B ($12.7B) plastics business, hoping to sway the German drugmaker from its plan to list the division in an IPO, Reuters reports.
- Advent, Carlyle and KKR reportedly are among P-E firms, as well as sovereign wealth funds and pension funds, considering MaterialScience after Bayer said in September that it planned to spin off the division through a stock listing.
- Market conditions for IPOs have weakened in recent weeks, forcing a number of companies to pull their listings and potentially heightening the attractiveness of a sale to P-E firms.
Oct. 21, 2014, 9:08 AM
- Privately-held Boehringer Ingelheim commences patient enrollment in a Phase 3 clinical trial evaluating the safety and efficacy of nintedanib in patients with colorectal cancer refractory to standard treatments. The double-blind randomized, placebo-controlled study will enroll more that 750 patients at 150 sites worldwide.
- Nintedanib (trade name Ofev) is a small molecule tyrosine kinase inhibitor that was recently approved by the FDA for idiopathic pulmonary fibrosis.
- CRC-related tickers: (NASDAQ:GILD) (NYSE:LLY) (NASDAQ:MGNX) (OTCPK:BAYRY) (OTCPK:BAYZF) (NASDAQ:AMGN) (OTC:MKGAF) (NYSE:BMY) (NASDAQ:ONXX) (NASDAQ:IMMU) (NASDAQ:ONCY) (NASDAQ:ARQL) (NYSE:SNY) (OTCQB:SNYNF) (NASDAQ:REGN)
Oct. 14, 2014, 3:44 PM
- Compugen (CGEN -0.4%) achieves the second preclinical milestone for one of the two checkpoint protein candidates in its previously-announced collaboration with Bayer HealthCare (OTCPK:BAYRY +0.2%)(OTCPK:BAYZF -0.4%). The event triggers a $6M payment from Bayer out of the $30M potential milestone payments related to the joint preclinical research for the two programs.
- The potential $30M in milestones are in addition to the $500M that Compugen can earn if the two programs are successful.
Oct. 8, 2014, 12:35 PM
- The FDA accepts and grants priority review of Roche unit Genentech's (OTCQX:RHHBY +0.1%) supplemental Biologics License Application (sBLA) of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy. The PDUFA date is February 6, 2015.
- Lucentis is currently cleared for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema.
- Related tickers: (REGN -0.4%)(AGN +1.1%)(ALIM +1%)(OTCPK:BAYRY +0.2%)(OTCPK:BAYZF)(PSDV -4.8%)
Oct. 6, 2014, 1:55 PM
- Privately-held Danbury, CT-based Perosphere enters into a third collaboration agreement with Daiichi Sankyo to study PER977, Perosphere's investigational anticoagulant reversal agent, in Phase 3 trials with edoxaban, Daiichi's investigational oral, once-daily factor Xa-inhibitor.
- In Phase 1 and 2 studies, PER977 showed that it directly binds to heparin as well as circulating direct factor Xa- and IIa-inhibitors reversing their anticoagulant effect. PER977 does not bind to blood coagulation factors or other blood proteins. In healthy volunteers, it reverses anticoagulant activity after a single IV dose of 100 mg - 300 mg and does not require an extended infusion in order to maintain the reversal.
- Under the terms of the agreement, Perosphere will seek FDA and EMA approval of PER977 to reverse anticoagulant activity of edoxaban and commercialize PER977 in the U.S. and EU. It retains full worldwide commercial rights to PER977. Perosphere will receive an upfront payment from Daiichi Sankyo as well as clinical development-related milestones. It plans to submit an NDA to the FDA by June 2015.
- Related tickers: (JNJ -0.4%)(OTCPK:BAYRY -0.4%)(OTCPK:BAYZF +0.1%)(PFE -0.3%)(BAX)(BMY -0.3%)(ISIS -1.9%)(PTLA)(AZN -0.1%)(MRK -0.6%)
Sep. 22, 2014, 7:46 AM
- The Japanese Ministry of Health, Labour and Welfare approves the use of Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) injection for the treatment of choroidal neovascularization (myopic CNV).
- Eylea is already approved for sale for neovascular age-related macular degeneration (wet AMD) and macular edema secondary to central vein occlusion (CRVO).
- Eylea is marketed in Japan by Bayer Healthcare's (OTCPK:BAYRY) (OTCPK:BAYZF) Japanese subsidiary Bayer Yakuhin, Ltd.
Sep. 18, 2014, 7:54 AM
- Following reports of a spin-off of its plastics business MaterialsScience, Bayer (OTCPK:BAYZF, OTCPK:BAYRY) has announced its plans to publicly list the unit.
- The move was approved by Bayer’s management board earlier this month and is expected to be considered by its supervisory board today.
- Bayer has not yet indicated to where or when it expects to list the shares of the division.
Sep. 17, 2014, 6:45 PM
- Bayer (OTCPK:BAYZF, OTCPK:BAYRY) plans to separate its plastics business, WSJ reports, a move that would further its shift away from its roots in chemicals and toward life sciences.
- Bayer could announce as soon as tomorrow a plan to shed the MaterialsScience unit, but the company reportedly has not decided what form the separation would ultimately take - an outright sale, IPO or spin off.
- The unit, which makes polycarbonate, polyurethane and other polymers had sales last year of €11.2B ($14.4B), down 2.2% Y/Y, and analysts have valued it at ~€10B, but in terms of growth, the business has underperformed Bayer's prescription drug and other life sciences operations.
Sep. 4, 2014, 7:51 AM
- Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) subsidiary Bayer Yakuhin, Ltd. submits a marketing authorization application to the Japanese Ministry of Health, Labour and Welfare for Eylea (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).
- Eylea is currently approved for use in Japan for neovascular (wet) age-related macular degeneration and macular edema secondary to central retinal vein occlusion.
- Marketing applications for Eylea for the treatment of choroidal neovascularization secondary to pathologic myopia and for the treatment of diabetic macular edema are currently under regulatory review.
- Related ticker: (REGN +0.7%)
Aug. 29, 2014, 9:05 AM
- People familiar with the situation say that the Belgian OTC drug maker Omega Pharma NV has attracted interest from a number of pharmaceutical companies including Perrigo (NYSE:PRGO), Boehringer Ingelheim, Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Sanofi (NYSE:SNY) (OTCQB:SNYNF).
- The tab for acquiring the business could be as high as 4B euros ($5.3B).
Aug. 25, 2014, 10:18 AM
- The FDA approves Iroko Pharmaceuticals' Zorvolex (diclofenac) for the management of osteoarthritis pain. The agency cleared the NSAID for the treatment of mild-to-moderate pain in adults in October 2013.
- Related tickers: (PFE +0.1%) (MRK +0.9%) (OTCPK:BAYZF) (OTCPK:BAYRY +1.2%) (OTCQX:RHHBY +0.6%) (TEVA -0.5%) (MYL +0.8%) (PRGO -0.1%) (GSK +0.8%)
BAYZF vs. ETF Alternatives
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. <br /> <br />Bayer HealthCare AG researches, develops, manufactures and markets... More
Other News & PR